TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04866342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM
Description: FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM
Description: FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA). By means of a modified closed-loop algorithm, the devise uses MasimoSET or Nellcor pulse oximetry to target a user-set SpO2 value.~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.
Study: NCT03801772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metronome
Description: Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
Study: NCT01385176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of investigational device system
Description: Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration during the randomization phase
Description: Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Titration after the randomization phase
Description: Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration after the randomization phase
Description: Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Blood Draw
Description: Blood draw before implant and 6 months after implant at the end of the randomization phase.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood draw before implant and 6 months after implant at the end of the randomization phase.
Study: NCT03358147

Intervention type: DRUG
Group type: OTHER
Intervention: Spiriva Respimat 2.5 μg
Description: Spiriva Respimat 2.5 μg QD (open-label)
Study: NCT05100680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomp
Description: Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
Study: NCT00988468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video Observation
Description: Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
Study: NCT03542734

Intervention type: OTHER
Intervention: multimodal magnetic resonance imaging
Description: multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI

Intervention type: OTHER
Intervention: multimodal magnetic resonance imaging
Description: multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
Study: NCT03099681

Intervention type: OTHER
Intervention: Treatment for Epitheloid Sarcoma
Description: Treatment Epitheloid Sarcoma according the disease guideline
Study: NCT02787369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Study: NCT00846742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stanford V Chemotherapy
Description: The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
Study: NCT01364675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin+Enalapril+Simvastatin
Description: Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Identical Placebo Tablet
Study: NCT01678027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAC triple therapy
Description: Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
Study: NCT04510974

Intervention type: OTHER
Intervention: Spinal Cord Injury
Description: Spinal Cord Injury

Intervention type: OTHER
Intervention: Spinal Cord Injury
Description: Spinal Cord Injury
Study: NCT02923427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask Supreme Evaluation
Description: Evaluation of clinical performance in terms of Insertion, ventilation and complications

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel Evaluation
Description: Evaluation of clinical performance in terms of Insertion,ventilation and complications
Study: NCT00145600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 Week Stanford V Chemotherapy
Description: 12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 cycles of VAMP chemotherapy
Description: 4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 alternating cycles of VAMP/COP chemotherapy
Description: 2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 alternating cycles of VAMP/COP chemotherapy
Description: 3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
Study: NCT01071473

Intervention type: OTHER
Group type: OTHER
Intervention: 12 Week Exercise Intervention
Description: Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
Study: NCT03051646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit
Description: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit
Description: Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Study: NCT03490968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Subjects will have 3 visits per week for 12 weeks.
Study: NCT06697652

Intervention type: PROCEDURE
Intervention: adrenalectomy
Description: adrenalectomy
Study: NCT01570777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal denervation and optimized medication regimen
Description: Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: optimized medication regimen
Description: Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
Study: NCT02954718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity training
Study: NCT03946111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Bupropion
Description: Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
Study: NCT02500927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8273 Capsules
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8273 Capsules A
Description: oral
Study: NCT02442544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: 1:1 oligofructose: inulin 8 g orally /day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin 3.3g orally/day
Study: NCT03553862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: collaborative care
Description: The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
Study: NCT04003974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod oral tablet
Description: Losmapimod will be administered with food when possible.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be administered with food when possible
Study: NCT03490968

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vascular Assessment
Description: Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated.
Study: NCT04145297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles
Study: NCT02705326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Speech
Description: Uses visual feedback of the tongue's motion to guide speech sound production
Study: NCT03941795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001(Toripalimab Injection)
Description: Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib 1 MG [Inlyta]
Description: Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JS001 and Axitinib
Description: Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years
Study: NCT04469400

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat diet intensive intervention
Description: education and Compound protein solid beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carbon Water Diet Intensive Intervention
Description: education and Nutrition bar
Study: NCT03144479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: right-sided double lumen tube
Description: Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: right-sided double lumen tube
Description: Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
Study: NCT00496067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler-Guided Uterine Artery Occlusion Device
Description: For bilateral occlusion of the uterine arteries
Study: NCT04598607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypidone Hydrochloride tablets
Description: 30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
Study: NCT00742274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore TAG Endoprosthesis
Description: Implant Gore TAG device with Best Medical therapy per physician discretion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Therapy
Description: Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
Study: NCT04531683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: same as described in experimental arm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: same as described in sham comparator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life style counselling
Description: life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: life style counselling
Description: life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: life style counselling
Description: life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
Study: NCT02861261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Berberine placebo tablets ; 2. ProMetS probiotics powder
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Berberine hydrochloride tablets; 2. Probiotics placebo powder
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1. Berberine placebo tablets; 2. Probiotics placebo powder
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night
Study: NCT02444442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Denervation
Description: Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Arterial access only. No delivery of radio frequency energy to renal arteries.
Study: NCT04471987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL12-L19L19
Description: Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL12-L19L19
Description: Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
Study: NCT02511561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201 (ciprofloxacin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201 (ciprofloxacin)
Study: NCT03490968

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vascular Assessment
Description: Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vascular Assessment
Description: Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated.
Study: NCT03395925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celon Pro Surge
Description: bipolar coagulation electrode intended for tissue heating